SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals, a biotech start-up in Salt Lake City, today announced the appointment of Robert Lollini, MBA, CPA, to its business advisory panel. Mr. Lollini is a distinguished leader in the life sciences, having served as President and Chief Executive Officer of IOMED, Inc. and Myrexis, Inc. Currently Mr. Lollini serves as the Chief Financial Officer of BioFire Diagnostics, a clinical diagnostics company recently acquired by the multinational biotechnology company BioMérieux.
Dr. Dean Y. Li, Co-founder and Chief Scientific Officer of Recursion and the Vice-Dean of Research at the University of Utah Health Sciences Center, adds: “Recursion is elated that Bob has joined our Business Advisory Panel. Bob has years of experience in building and running biotech companies here in the Mountain West. His deep financial expertise, especially in the context of business-building in the life sciences, will be a tremendous asset for our growing company. His experience across a variety of aspects of biotechnology, from pharmaceutical development to diagnostics, will be invaluable as Recursion applies its technology in a variety of similar areas… I am excited personally as well, both in my Recursion and University positions, to understand at a deeper level how BioFire has so ingeniously navigated the space to become such a shining success with roots here at the University of Utah.”
Mr. Lollini added: “I was intrigued at the onset when I learned about Recursion’s technology platform. The ability to rapidly screen approved drugs and other compounds in various stages of development, for therapeutic activity against new disease targets enhances the economic feasibility of finding therapeutics to treat these rare diseases by offering significant potential benefit in reducing the time, cost and risk of development and approval. I am excited to work with Chris, Dr. Li and other members of the Advisory Board to help guide the advancement of this technological breakthrough.”
Mr. Lollini, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including business strategy and business development.
Robert Lollini, MBA, CPA – Mr. Lollini has served as Chief Financial Officer of BioFire Diagnostics since October of 2012. BioFire Diagnostics is a privately held clinical diagnostics company manufacturing the FilmArray System. Prior to his work with BioFire, Mr. Lollini was the Chief Financial Officer from 2009 to 2011 and Chief Executive Officer through 2012 of NASDAQ-listed Myrexis, Inc. Mr. Lollini held a variety of executive positions at IOMED, Inc., an AMEX-traded drug delivery company between 1993 and 2007. Prior to his work with IOMED, he held various executive management positions at R.P. Scherer Corporation, a developer of oral drug delivery systems. Mr. Lollini started his career with the accounting firm Arthur Andersen & Co. Mr. Lollini is a Certified Public Accountant. He received a Bachelor of Arts degree in Accounting from Michigan State University and an MBA in Finance and Economics from the University of Detroit Mercy.
About Recursion Pharmaceuticals – Recursion Pharmaceuticals, LLC, is a drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition known drugs and shelved pharmaceutical assets to treat rare genetic diseases. The company’s focus on rare genetic diseases is much-needed, as there are more than 5,000 such conditions that together affect millions of Americans, and more than 95% of these diseases have no approved therapy. Recursion’s novel drug screening platform combines experimental biology and bioinformatics in a massively parallel system to quickly and efficiently identify treatments for multiple rare genetic diseases. The core of the approach revolves around high-throughput automated screening using high-content assays in human cells, which allows the near simultaneous modeling of hundreds of genetic diseases. Rich data from these assays is probed using advanced statistical and machine learning approaches, and the effects of thousands of known drugs and shelved drug candidates can be investigated efficiently to identify those holding the most promise for the treatment of any one rare genetic disease.
See www.recursionpharma.com for more information.
